- Study also points to potential of pre-treatment R2 levels as a possible
predictor of clinical activity -
TORONTO, July 2 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced publication by an Ohio State University (OSU) clinical team of a paper entitled "Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia" (Clinical Cancer Research 2008; 14 (12): 3889-3895). This was the first clinical study in AML with GTI-2040, now known as LOR-2040.
The primary author, Dr Rebecca Klisovic and the Principal Investigator, Dr Guido Marcucci, in the Division of Hematology and Oncology at OSU carried out the study under the sponsorship of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). Lorus is collaborating with the Division of Cancer Treatment and Diagnosis, NCI on the development of LOR-2040 under a Clinical Trials Agreement. All patients in the study received LOR-2040 and high dose cytarabine in therapeutic doses within a dose escalating design, which determined a well-tolerated recommended Phase II dose.
In this study, the authors examined the relationship of the targeted
activity of LOR-2040 to clinical responses in AML patients less than 60
years of age. Downregulation of R2, the target of LOR-2040, after 24 hours
of LOR-2040 was statistically significant and was associated with complete
remission. The authors have also now reported for the first time that
outcomes of complete response were associated with high pre-treatment
levels of R2, which were statistically significant compared to
nonresponders. This finding suggests that pre-treatment R2 levels may be a
predictor of response, and provid
|SOURCE Lorus Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved